Source comparison
PT-141 Pharmacology Studies: Comparison to Alternative Mechanisms
PT-141 (bremelanotide) Melanocortin receptor agonist MC4R (central) 45 minutes subcutaneous Transient BP elevation 2–5 mmHg, resolves in 24 hours Premenopausal HSDD (desire disorder) PDE5 Inhibitors (sildenafil, tadalafil) Phosphodiesterase-5 inhibition → cGMP
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- Melanocortin receptor agonist
- MC4R (central)
- 45 minutes subcutaneous
- Transient BP elevation 2–5 mmHg, resolves in 24 hours
- Premenopausal HSDD (desire disorder)
- PDE5 Inhibitors (sildenafil, tadalafil)
- Phosphodiesterase-5 inhibition → cGMP elevation
- PDE5 (peripheral vascular smooth muscle)
- 30–60 minutes oral
- Vasodilation, contraindicated with nitrates
- Erectile dysfunction (men only)
- Flibanserin (Addyi)
- 5-HT1A agonist / 5-HT2A antagonist
- Serotonin receptors (central)
- Daily dosing, effects build over 4–8 weeks
- Hypotension, syncope with alcohol
- Premenopausal HSDD
- Testosterone (off-label)
- Androgen receptor agonist
- Androgen receptor (multiple tissues)
- Weeks to months (depending on formulation)
- Lipid changes, virilization risk in women
- Hypogonadism (men), off-label HSDD
- Apomorphine (sublingual)
- Non-selective dopamine agonist
- D1, D2 dopamine receptors (central)
- 20 minutes sublingual
- Nausea 70%, orthostatic hypotension
- Erectile dysfunction (Europe only)
- Professional Assessment
- PT-141 is the only FDA-approved compound for HSDD that acts on central arousal pathways. Its pharmacology is distinct from vascular or hormonal interventions, making direct comparisons difficult. The transient nausea and BP effects are dose-limiting for some patients but less severe than the sedation/hypotension profile of flibanserin or the cardiovascular contraindications of PDE5 inhibitors.